$Mrk SVB Leerink On Merck Price Target Raise: Firm Highlights Molnupiravir In Treating Covid-19 Patients With Symptoms <5 Days & At Least One Risk Factor For Severe Diseases; Notes 1.7M Supply Commitment To U.S. & Guided Manufacturing Capacity of 10M